Showing 3241-3250 of 3314 results for "".
- A Daily Orange May Reduce AMD Risk, Study Findshttps://modernod.com/news/a-daily-orange-may-reduce-amd-risk-study-finds/2479986/People who consume at least one orange per day have a 60% lower risk of developing age-related macular degeneration (AMD) 15 years later compared with those who do not eat oranges, a study has found, according to a report in Medscape.
- Aura Biosciences Presents Interim Phase 1b/2 Data at ASRShttps://modernod.com/news/aura-biosciences-presents-interim-phase-1b-2-data-at-asrs/2479994/Aura Biosciences presented interim data from an open-label phase 1b/2 study of its lead program, light-activated AU-011 for the treatment of primary choroidal melanoma, at the 36th annual American Society of Retina Specialists (ASRS) meeting in Vancouver, Canada. The findings were presented by Am
- Researchers Take Step Closer to Developing AMD Eye Dropshttps://modernod.com/news/researchers-take-step-closer-to-developing-amd-eye-drops/2480007/Scientists at the University of Birmingham, UK, say they are one step closer to developing an eye drop that could revolutionize treatment for age-related macular degeneration (AMD), according to a university news release. Scientists led by biochemist Felicity de Cogan, PhD, from the Univer
- Ocular Therapeutix Announces FDA Acceptance of NDA Resubmission for Dextenzahttps://modernod.com/news/ocular-therapeutix-announces-fda-acceptance-of-nda-resubmission-for-dextenza/2480009/Ocular Therapeutix announced that it has received acknowledgement from the FDA that the new drug application (NDA) for Dextenza has been received. Dextenza (dexamethasone insert) 0.4 mg is Ocular Therapeutix’s lead product candidate for the treatment of ocular pain following ophthalmic surgery. T
- Bausch + Lomb Retina News, Eventshttps://modernod.com/news/bausch-lomb-retina-news-events/2480011/In advance of this week’s ASRS meeting, Bausch + Lomb Vice President and general manager of Surgical, Chuck Hess, distributed a customer letter to surgeons providing them an update on our progress in retina. The letter is below: Dear Eye Care Professional: At this time last y
- The Foundation Fighting Blindness Presents the Emerging Science Showcase at OIS Retina 2018https://modernod.com/news/the-foundation-fighting-blindness-presents-the-emerging-science-showcase-at-ois-retina-2018/2480012/The Foundation Fighting Blindness (FFB) Emerging Science Showcase will lead off the upcoming Ophthalmology Innovation Summit for Retina, held July 20, 2018, in Vancouver, B.C., Canada. Moderated by FFB COO Jaso
- Practice-Hospital Consolidation Increasing for Many Specialtieshttps://modernod.com/news/practice-hospital-consolidation-increasing-for-many-specialties/2480021/The level of integration of certain primary care practices into health systems and hospitals more than doubled in recent years, with steeper increases seen in the fields of oncology and cardiology, according to research publish
- CHOP Researchers Develop Highly Specific Predictive Screening Tool for Retinopathy in Premature Infantshttps://modernod.com/news/chop-researchers-develop-highly-specific-predictive-screening-tool-for-retinopathy-in-premature-infants/2480024/A multi-hospital collaboration led by researchers at Children’s Hospital of Philadelphia (CHOP) has found a simple method of determining which premature infants should be screened for retinopathy of prematurity (ROP). The recommendations have the potential t
- Zeiss Names New Chief Financial Officerhttps://modernod.com/news/zeiss-names-news-chief-financial-officer/2480025/Christian Müller, PhD, will become Chief Financial Officer of Carl Zeiss AG, succeeding Thomas Spitzenpfeil who, as previously announced, will leave the company. Dr. Müller has been CFO of the Zeiss subsidiary Carl Zeiss Meditec AG since 2009. He joined the Zeiss Group in 2002 as head of Corporat
- Lightmed Announces New Office Location in Caesarea, Israelhttps://modernod.com/news/lightmed-announces-new-office-location-in-caesarea-israel/2480027/Lightmed announced it has opened a new office location in Caesarea, Israel to expand its business and technological investments, and leverage Israel’s diverse and experienced medical technology talent pool. “Th